EP PerMed 2027 — Cell and Gene Therapies for Personalised Medicine (Turkey participation)

Reference

EP-PERMED-CGT4PM2027-TR

Agency

Posted

2026-11-10

Deadline

2027-01-20

Source status

open at verification — international consortium and national application required at retrieval

Country

Turkey (funding region); applicant eligibility varies

Record type

Specific call

Listing numbers

Not specified

Retrieved

2026-11-11

Programme overview

The 2027 joint call supports development and validation of innovative cell and gene therapies for personalised human medicine. Approaches include somatic-cell therapies, gene therapies, combined cell/gene therapies and specified biological products. Proposals are submitted by multinational consortia through a two-stage international process.

Who should check this opportunity?

Participating Turkish researchers must also submit a national application to TÜBİTAK. The national route uses programme 1071; consortium and national eligibility rules both apply.

Prepare your application

1. Check consortium composition, scientific scope and national eligibility.
2. Coordinate the international short proposal before 20 January 2027, 14:00 CET.
3. Complete the separate TÜBİTAK national application and any later stages on their own schedules.

Use the funder’s current forms. This checklist does not submit an application or complete a contract.

Source timing: International short proposal: 20 January 2027, 14:00 CET. National submissions and later stages have separate deadlines; consult the official call timetable.

Read the official call before applying

Check the full description, funding amounts, eligibility, required documents and any amendments with the official funder. Additional restrictions and application instructions may not be included in this directory.